These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
801 related articles for article (PubMed ID: 37790630)
41. Wu C; Dong B; Huang L; Liu Y; Ye G; Li S; Qi Y Front Oncol; 2021; 11():754290. PubMed ID: 34745988 [TBL] [Abstract][Full Text] [Related]
42. NGEF is a potential prognostic biomarker and could serve as an indicator for immunotherapy and chemotherapy in lung adenocarcinoma. Chen X; Zhang T; He YQ; Miao TW; Yin J; Ding Q; Yang M; Chen FY; Zeng HP; Liu J; Zhu Q BMC Pulm Med; 2024 May; 24(1):248. PubMed ID: 38764064 [TBL] [Abstract][Full Text] [Related]
43. [Mutational Signatures Analysis of Micropapillary Components and Exploration of ZNF469 Gene in Early-stage Lung Adenocarcinoma with Ground-glass Opacities]. Xu Y; Sun Q; Wang S; Zhu H; Dong G; Meng F; Xia Z; You J; Kong X; Wu J; Chen P; Yuan F; Yu X; Ji J; Li Z; Zhu P; Sun Y; Liu T; Yin R; Xu L Zhongguo Fei Ai Za Zhi; 2024 Jan; 26(12):889-900. PubMed ID: 38151328 [TBL] [Abstract][Full Text] [Related]
44. Establishment of a prognostic signature for lung adenocarcinoma by integration of 7 pyroptosis-related genes and cross-validation between the TCGA and GEO cohorts: A comprehensive bioinformatics analysis. Zhang W; Wan S; Qu Z; Ge J; Zhang C; Li C; Jiang Y Medicine (Baltimore); 2022 Jul; 101(29):e29710. PubMed ID: 35866781 [TBL] [Abstract][Full Text] [Related]
45. Integrated bioinformatics analysis of microarray data from the GEO database to identify the candidate genes linked to poor prognosis in lung adenocarcinoma. Liu X; Li L; Xie X; Zhuang D; Hu C Technol Health Care; 2023; 31(2):579-592. PubMed ID: 36336945 [TBL] [Abstract][Full Text] [Related]
46. Bioinformatics analysis of an immunotherapy responsiveness-related gene signature in predicting lung adenocarcinoma prognosis. Jiang Y; Hammad B; Huang H; Zhang C; Xiao B; Liu L; Liu Q; Liang H; Zhao Z; Gao Y Transl Lung Cancer Res; 2024 Jun; 13(6):1277-1295. PubMed ID: 38973963 [TBL] [Abstract][Full Text] [Related]
47. In silico analysis reveals PRR11 as a prognostic and oncogenic marker in lung adenocarcinoma. Hu A; Tang K; Liu J; Han X; Chen Q Medicine (Baltimore); 2023 May; 102(21):e33755. PubMed ID: 37233443 [TBL] [Abstract][Full Text] [Related]
48. Construction and validation of a prognostic model for lung adenocarcinoma based on endoplasmic reticulum stress-related genes. Li F; Niu Y; Zhao W; Yan C; Qi Y Sci Rep; 2022 Nov; 12(1):19857. PubMed ID: 36400857 [TBL] [Abstract][Full Text] [Related]
49. High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle. Tang X; Zhou H; Liu Y Dis Markers; 2023; 2023():9292536. PubMed ID: 36712920 [TBL] [Abstract][Full Text] [Related]
50. Gene expression and prognosis of x-ray repair cross-complementing family members in non-small cell lung cancer. Fan Y; Gao Z; Li X; Wei S; Yuan K Bioengineered; 2021 Dec; 12(1):6210-6228. PubMed ID: 34486486 [TBL] [Abstract][Full Text] [Related]
51. H2A Histone Family Member Z (H2AFZ) Serves as a Prognostic Biomarker in Lung Adenocarcinoma: Bioinformatic Analysis and Experimental Validation. Li Z; Hu M; Qiu J; Feng J; Zhang R; Wu H; Hu G; Ren J Med Sci Monit; 2022 Jan; 28():e933447. PubMed ID: 35027526 [TBL] [Abstract][Full Text] [Related]
52. High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma. Jin CY; Du L; Nuerlan AH; Wang XL; Yang YW; Guo R Aging (Albany NY); 2020 Dec; 13(3):3518-3535. PubMed ID: 33411689 [TBL] [Abstract][Full Text] [Related]
53. Pan-cancer analysis of UBE2T with a focus on prognostic and immunological roles in lung adenocarcinoma. Cao K; Ling X; Jiang X; Ma J; Zhu J Respir Res; 2022 Nov; 23(1):306. PubMed ID: 36357897 [TBL] [Abstract][Full Text] [Related]
54. Six CT83-related Genes-based Prognostic Signature for Lung Adenocarcinoma. Wang Y; Zhang G; Wang R Comb Chem High Throughput Screen; 2022; 25(9):1565-1575. PubMed ID: 34259140 [TBL] [Abstract][Full Text] [Related]
55. Identification and validation of a novel cuproptosis-related signature as a prognostic model for lung adenocarcinoma. Chen Y; Tang L; Huang W; Zhang Y; Abisola FH; Li L Front Endocrinol (Lausanne); 2022; 13():963220. PubMed ID: 36353226 [TBL] [Abstract][Full Text] [Related]
56. The Effect of GLUT1 on the Survival Rate and Immune Cell Infiltration of Lung Adenocarcinoma and Squamous Cell Carcinoma: A Meta and Bioinformatics Analysis. Zhang G; Dong R; Kong D; Liu B; Zha Y; Luo M Anticancer Agents Med Chem; 2022; 22(2):223-238. PubMed ID: 34238200 [TBL] [Abstract][Full Text] [Related]
57. Pan-cancer analysis identifies Yang H; Wei X; Zhang L; Xiang L; Wang P Transl Cancer Res; 2022 Aug; 11(8):2902-2916. PubMed ID: 36093552 [TBL] [Abstract][Full Text] [Related]
58. The value of CEP55 gene as a diagnostic biomarker and independent prognostic factor in LUAD and LUSC. Fu L; Wang H; Wei D; Wang B; Zhang C; Zhu T; Ma Z; Li Z; Wu Y; Yu G PLoS One; 2020; 15(5):e0233283. PubMed ID: 32437446 [TBL] [Abstract][Full Text] [Related]
59. The identification of key biomarkers in patients with lung adenocarcinoma based on bioinformatics. Ni KW; Sun GZ Math Biosci Eng; 2019 Aug; 16(6):7671-7687. PubMed ID: 31698633 [TBL] [Abstract][Full Text] [Related]
60. RACGAP1 is a pivotal gene in lung adenocarcinoma-associated membranous nephropathy: Based on comprehensive bioinformatics analysis and machine learning. Xu Q; Li J; Zhuo L; Gao H; Yang Y; Li W Int Immunopharmacol; 2024 Sep; 139():112783. PubMed ID: 39068752 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]